NY State Senate Bill 2025-S2625

Senate Bill S2625

2025-2026 Legislative Session

Relates to enhancing patient access to medication assisted treatment for treatment of opioid disease

download bill text pdf

Current Bill Status - In Senate Committee Health Committee

Introduced
- In Committee Assembly
- In Committee Senate
- On Floor Calendar Assembly
- On Floor Calendar Senate
- Passed Assembly
- Passed Senate
Delivered to Governor
Signed By Governor

Please enter your contact information

First Name

Last Name

Email Address

A valid email address is required.

Home address is used to determine the senate district in which you reside. Your support or opposition to this bill is then shared immediately with the senator who represents you.

Optional services from the NY State Senate:

Create an account. An account allows you to officially support or oppose key legislation, sign petitions with a single click, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Include a custom message for your Senator? (Optional)

Enter a message to your senator. Many New Yorkers use this to share the reasoning behind their support or opposition to the bill. Others might share a personal anecdote about how the bill would affect them or people they care about.

Actions

View Actions

	Assembly Actions - Lowercase Senate Actions - UPPERCASE
Jan 21, 2025	referred to health

2025-S2625 (ACTIVE) - Details

Current Committee:: Senate Health
Law Section:: Public Health Law
Laws Affected:: Amd §§3331, 206 & 3381, Pub Health L; amd §§6801 & 6527, Ed L

2025-S2625 (ACTIVE) - Summary

Allows a licensed pharmacist to prescribe and order FDA-approved medication assisted therapy under a non-patient-specific regimen for the treatment of opioid use disease.

2025-S2625 (ACTIVE) - Sponsor Memo

                                 
BILL NUMBER: S2625

SPONSOR: FERNANDEZ
 
TITLE OF BILL:

An act to amend the public health law and the education law, in relation
to enhancing patient access to medication assisted treatment for treat-
ment of opioid disease

 
SUMMARY OF SPECIFIC PROVISIONS:

Section 1 amends section 3331 of public health law by adding a subdivi-
sion that authorizes pharmacists to administer and dispense substances
listed in schedules III, IV, and V for the treatment of opioid use
disorder.

Section 2 amends section 6801 of education law by adding a subdivision
that authorizes pharmacists to prescribe FDA-approved medication
assisted therapy under a non-patient-specific regimen for the treatment
of opioid use disorder.

Section 3 amends subdivision 1 of chapter 206 of public health law by
adding a paragraph that directs the commissioner of health to establish

a statewide protocol for pharmacist prescribing of medication assisted
treatment of opioid use disorder.

Section 4 amends paragraph (e) of subdivision 4 of section 3381 of the
public health by authorizing licensed pharmacists to offer medication
assisted treatment for opioid use disorder.

Section 5 amends section 6527 of education law by adding a subdivision
that authorizes licensed physicians to prescribe and order a non-pa-
tient-specific regimen to a licensed pharmacist, for prescribing bupre-
norphine for the care of patients with opioid use disorder.

Section 6 establishes the effective date.

 
JUSTIFICATION:

As individuals struggle with substance use disorder, we need an all-
hands-on deck approach to make sure care is accessible throughout New
York State. This bill allows a physician and pharmacist to enter into a
collaborate agreement to increase the number of individuals authorized
to prescribe buprenorphine. The bill allows a physician to provide a
non-patient specific order to the pharmacist for buprenorphine.

The federal government has recently taken steps to increase the avail-
ability of buprenorphine. With the passage of the bipartisan Mainstream-
ing Addiction Treatment Act, Congress removed regulations requiring
potential prescribers to register with the federal government. Buprenor-
phine, one of three medications approved by the Food and Drug Adminis-
tration for the treatment for OUD, reduces the risk of overdose, illicit
opioid use, and the transmission of infectious disease that can accompa-
ny injection drug use. With the registration requirement gone, health
care providers with state and federal authority to prescribe narcotics
can now prescribe buprenorphine.

However, Buprenorphine prescribing remains low, despite the drug's over-
all effectiveness and safety as a treatment for OUD. From 2016 through
2019, 20% of Medicare patients with OUD filled prescriptions for bupre-
norphine, according to a recent study in the New England Journal of
Medicine. Racial disparities also exist in prescribing of the drug, with
white patients being 80% more likely to receive a prescription than
Black patients and 25% more likely to receive a prescription than Latino
patients. Additionally, some office-based practices are hesitant to
accept new patients however pharmacies are the most accessible health
care provider.

States such as Nevada and Rhode Island have authorized physicians to
collaborate with pharmacists to assess patients and if appropriate
prescribe buprenorphine. Specifically in Rhode Island, a pilot study
tracked the experiences of 100 patients who started taking buprenorphine
after visiting a trained pharmacist for their care.  Once stabilized on
the medication, 58 patients were randomly assigned to receive either
continued care in the pharmacy or usual care in a clinic or physician's
office. After one month, the patients in the pharmacy care group showed
dramatically higher rates of retention: 25 patients (89%) continued to
receive treatment in the pharmacy compared to five (17%) in the usual
care group. A third of patients in the study identified as Black,
Indigenous, or persons of color, and almost half were without a perma-
nent residence.

With 6,000 pharmacies in New York State, pharmacists are widely accessi-
ble and represent enormous potential to connect patients suffering from
opiate use disorders to highly competent health care professionals and
ongoing care. This legislation is yet another tool to reduce barriers to
care for those who struggle with SUD utilizing the collaboration between
a physician and pharmacist.

 
PRIOR LEGISLATIVE HISTORY:

2023-2024: A.6778

 
FISCAL IMPLICATIONS:

None.

 
EFFECTIVE DATE:
This act shall take effect on the one hundred eightieth day after it
shall have become a law.

2025-S2625 (ACTIVE) - Bill Text download pdf

                             
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                   2625
 
                        2025-2026 Regular Sessions
 
                             I N  S E N A T E
 
                             January 21, 2025
                                ___________
 
 Introduced by Sen. FERNANDEZ -- read twice and ordered printed, and when
   printed to be committed to the Committee on Health
 
 AN ACT to amend the public health law and the education law, in relation
   to  enhancing  patient  access  to  medication  assisted treatment for
   treatment of opioid disease

   THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section  1. Section 3331 of the public health law is amended by adding
 a new subdivision 10 to read as follows:
   10. A PHARMACIST, IN GOOD FAITH, AND IN THE USUAL  COURSE  OF  PROFES-
 SIONAL   PHARMACY  PRACTICE,  MAY  PRESCRIBE,  ADMINISTER  AND  DISPENSE
 SUBSTANCES LISTED IN SCHEDULES III, IV,  AND  V  FOR  THE  TREATMENT  OF
 OPIOID USE DISORDERS, AS PROVIDED IN TITLES III OR V OF THIS ARTICLE.
   §  2.    Section  6801 of the education law is amended by adding a new
 subdivision 10 to read as follows:
   10. (A) A LICENSED PHARMACIST MAY  PRESCRIBE  FDA-APPROVED  MEDICATION
 ASSISTED  THERAPY UNDER A NON-PATIENT-SPECIFIC REGIMEN FOR THE TREATMENT
 OF OPIOID USE DISEASE IN ACCORDANCE WITH SUBDIVISION TWELVE  OF  SECTION
 SIXTY-FIVE HUNDRED TWENTY-SEVEN OF THIS TITLE AND REGULATIONS PROMULGAT-
 ED  BY  THE COMMISSIONER OF HEALTH ESTABLISHED PURSUANT TO PARAGRAPH (X)
 OF SUBDIVISION ONE OF SECTION TWO HUNDRED SIX OF THE PUBLIC  HEALTH  LAW
 IN CONSULTATION WITH THE COMMISSIONER.
   (B) A LICENSED PHARMACIST AUTHORIZED TO ISSUE A PRESCRIPTION FOR MEDI-
 CATION ASSISTED TREATMENT OF OPIOID USE DISORDER SHALL:
   (I)    REGISTER  WITH  THE FEDERAL DRUG ENFORCEMENT ADMINISTRATION AND
 COMPLETE  THE  TRAINING  REQUIRED  BY  SECTION  303  OF  THE  CONTROLLED
 SUBSTANCES ACT (21 USC 823);
   (II)  PROVIDE INFORMATION TO THE PATIENT ON THE IMPORTANCE OF HAVING A
 PRIMARY HEALTH CARE  PRACTITIONER,  DEVELOPED  BY  THE  COMMISSIONER  OF
 HEALTH;
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.
                                                            LBD05761-03-5
 S. 2625                             2

 
   (III) REPORT SUCH ADMINISTRATION BY ELECTRONIC TRANSMISSION OR FACSIM-
 ILE TO THE PATIENT'S ATTENDING PRIMARY HEALTH CARE PRACTITIONER OR PRAC-
 TITIONERS, IF ANY; AND
   (IV) REFER PATIENT TO PROVIDER OR PRACTICE RESPONSIBLE FOR COLLABORAT-
 ING IN THE NON-PATIENT-SPECIFIC REGIMEN.
   §  3. Subdivision 1 of section 206 of the public health law is amended
 by adding a new paragraph (x) to read as follows:
   (X) ESTABLISH A STATEWIDE PROTOCOL FOR PHARMACIST PRESCRIBING OF MEDI-
 CATION ASSISTED TREATMENT OF OPIOID USE DISORDER, NOT LATER THAN  NINETY
 DAYS  AFTER THE EFFECTIVE DATE OF THIS PARAGRAPH.  A LICENSED PHARMACIST
 AUTHORIZED TO ISSUE A PRESCRIPTION FOR MEDICATION ASSISTED TREATMENT  OF
 OPIOID  USE  DISORDER  SHALL  REGISTER WITH THE FEDERAL DRUG ENFORCEMENT
 ADMINISTRATION AND COMPLETE THE TRAINING REQUIRED BY SECTION 303 OF  THE
 CONTROLLED SUBSTANCES ACT (21 USC 823).
   §  4.  Paragraph  (e)  of  subdivision 4 of section 3381 of the public
 health law, as amended by chapter 433 of the laws of 2021, is amended to
 read as follows:
   (e) A pharmacy registered under article one  hundred  thirty-seven  of
 the  education law may offer counseling and referral services to custom-
 ers purchasing  hypodermic  syringes  for  the  purpose  of:  preventing
 injection  drug  abuse;  the provision of drug treatment; preventing and
 treating hepatitis C; preventing drug overdose; testing  for  the  human
 immunodeficiency  virus; and providing pre-exposure prophylaxis and non-
 occupational post-exposure prophylaxis. The content of  such  counseling
 and  referral shall be at the professional discretion of the pharmacist.
 A LICENSED PHARMACIST AUTHORIZED TO ISSUE PRESCRIPTIONS  FOR  MEDICATION
 ASSISTED  TREATMENT  PURSUANT TO SUBDIVISION TEN OF SECTION THIRTY-THREE
 HUNDRED THIRTY-ONE OF THIS ARTICLE MAY OFFER MEDICATION ASSISTED  TREAT-
 MENT.
   §  5.  Section  6527  of  the education law is amended by adding a new
 subdivision 12 to read as follows:
   12. A LICENSED PHYSICIAN MAY PRESCRIBE AND ORDER A NON-PATIENT-SPECIF-
 IC REGIMEN TO A LICENSED PHARMACIST, FOR PRESCRIBING  BUPRENORPHINE  FOR
 THE  CARE  OF  PATIENTS WITH OPIOID USE DISORDER PURSUANT TO SUBDIVISION
 TEN OF SECTION SIXTY-EIGHT HUNDRED ONE OF THIS TITLE.
   § 6. This act shall take effect on the one hundred eightieth day after
 it shall have become a law.

Comments

Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.

Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.

Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.